Literature DB >> 32073605

Uncovering novel susceptibility targets to enhance the efficacy of third-generation cephalosporins against ESBL-producing uropathogenic Escherichia coli.

Minh-Duy Phan1,2, Amy L Bottomley3, Kate M Peters1,2, Elizabeth J Harry3, Mark A Schembri1,2.   

Abstract

BACKGROUND: Uropathogenic Escherichia coli (UPEC) are a major cause of urinary tract infection (UTI), one of the most common infectious diseases in humans. UPEC are increasingly associated with resistance to multiple antibiotics. This includes resistance to third-generation cephalosporins, a common class of antibiotics frequently used to treat UTI.
METHODS: We employed a high-throughput genome-wide screen using saturated transposon mutagenesis and transposon directed insertion-site sequencing (TraDIS) together with phenotypic resistance assessment to identify key genes required for survival of the MDR UPEC ST131 strain EC958 in the presence of the third-generation cephalosporin cefotaxime.
RESULTS: We showed that blaCMY-23 is the major ESBL gene in EC958 responsible for mediating resistance to cefotaxime. Our screen also revealed that mutation of genes involved in cell division and the twin-arginine translocation pathway sensitized EC958 to cefotaxime. The role of these cell-division and protein-secretion genes in cefotaxime resistance was confirmed through the construction of mutants and phenotypic testing. Mutation of these genes also sensitized EC958 to other cephalosporins.
CONCLUSIONS: This work provides an exemplar for the application of TraDIS to define molecular mechanisms of resistance to antibiotics. The identification of mutants that sensitize UPEC to cefotaxime, despite the presence of a cephalosporinase, provides a framework for the development of new approaches to treat infections caused by MDR pathogens.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32073605     DOI: 10.1093/jac/dkaa023

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Plasmids shape the diverse accessory resistomes of Escherichia coli ST131.

Authors:  Arun Gonzales Decano; Nghia Tran; Hawriya Al-Foori; Buthaina Al-Awadi; Leigh Campbell; Kevin Ellison; Louisse Paolo Mirabueno; Maddy Nelson; Shane Power; Genevieve Smith; Cian Smyth; Zoe Vance; Caitriona Woods; Alexander Rahm; Tim Downing
Journal:  Access Microbiol       Date:  2020-11-18

2.  Nitrofurantoin Combined With Amikacin: A Promising Alternative Strategy for Combating MDR Uropathogenic Escherichia coli.

Authors:  Zi-Xing Zhong; Ze-Hua Cui; Xiao-Jie Li; Tian Tang; Zi-Jian Zheng; Wei-Na Ni; Liang-Xing Fang; Yu-Feng Zhou; Yang Yu; Ya-Hong Liu; Xiao-Ping Liao; Jian Sun
Journal:  Front Cell Infect Microbiol       Date:  2020-12-21       Impact factor: 5.293

Review 3.  "Omics" Technologies - What Have They Told Us About Uropathogenic Escherichia coli Fitness and Virulence During Urinary Tract Infection?

Authors:  Sergi Torres-Puig; Vanesa García; Kristian Stærk; Thomas E Andersen; Jakob Møller-Jensen; John E Olsen; Ana Herrero-Fresno
Journal:  Front Cell Infect Microbiol       Date:  2022-02-14       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.